Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2017 Sep/Oct;32(5):332-342.
doi: 10.1097/HTR.0000000000000322.

Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial

Affiliations
Randomized Controlled Trial

Sertraline for Major Depression During the Year Following Traumatic Brain Injury: A Randomized Controlled Trial

Jesse R Fann et al. J Head Trauma Rehabil. 2017 Sep/Oct.

Abstract

Objective: Major depressive disorder (MDD) is common and associated with impaired functioning after traumatic brain injury (TBI). Few placebo-controlled antidepressant trials exist in this population. We evaluated the efficacy and tolerability of sertraline for MDD within 1 year of sustaining a TBI.

Setting: Level I trauma center.

Participants: Adults with MDD within 1 year of hospitalization for complicated mild to severe TBI.

Design: Randomized, double-blind, placebo-controlled trial.

Main measures: Twelve-week treatment response on the 17-item Hamilton Depression Rating Scale. We also assessed symptom improvement and remission.

Results: We randomized 62 participants: 32% sustained a severe TBI, 68% had significant anxiety, 63% had a history of prior MDD, and 69% had a history of alcohol or drug dependence. Depression significantly improved from baseline to 12 weeks in both treatment groups (P < .001). There were no significant differences between the sertraline and placebo groups over 12 weeks on depression severity, response, or remission. The sertraline group had significant improvement on speed of information processing compared with the placebo group (P < .006).

Conclusion: Sertraline monotherapy was not superior to placebo for MDD in people with post-acute complicated mild to severe TBI. Research is needed on the effectiveness of interventions that also address the significant psychosocial needs of this population.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

No other disclosures were reported.

Figures

Figure 1
Figure 1
Flow of Participants in the Trial
Figure 2
Figure 2
Mean Scores for the Sertraline and Placebo Groups a. Hamilton Depression Rating Scale 17-item version b. Hamilton Depression Rating Scale Maier subscale
Figure 2
Figure 2
Mean Scores for the Sertraline and Placebo Groups a. Hamilton Depression Rating Scale 17-item version b. Hamilton Depression Rating Scale Maier subscale

Similar articles

Cited by

References

    1. Bombardier CH, Fann JR, Temkin NR, Esselman PC, Barber J, Dikmen SS. Rates of major depressive disorder and clinical outcomes following traumatic brain injury. Jama. 2010;303(19):1938–1945. - PMC - PubMed
    1. Hart T, Fann JR, Chervoneva I, et al. Prevalence, Risk Factors, and Correlates of Anxiety at 1 Year After Moderate to Severe Traumatic Brain Injury. Arch Phys Med Rehabil. 2016;97(5):701–707. - PubMed
    1. Fann JR, Katon WJ, Uomoto JM, Esselman PC. Psychiatric disorders and functional disability in outpatients with traumatic brain injuries. Am J Psychiatry. 1995;152(10):1493–1499. - PubMed
    1. Hammond FM, Barrett RS, Shea T, et al. Psychotropic Medication Use During Inpatient Rehabilitation for Traumatic Brain Injury. Arch Phys Med Rehabil. 2015;96(8 Suppl):S256–253 e214. - PMC - PubMed
    1. Ashman TA, Cantor JB, Gordon WA, et al. A randomized controlled trial of sertraline for the treatment of depression in persons with traumatic brain injury. Arch Phys Med Rehabil. 2009;90(5):733–740. - PubMed

Publication types

MeSH terms